DOQUALAST

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H8N2O3
Molecular Weight	240.2142
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC2=C(C=C1)N=C3C=CC=CN3C2=O

InChI

InChIKey=HMZDSBSMNLBGIW-UHFFFAOYSA-N

InChI=1S/C13H8N2O3/c16-12-9-7-8(13(17)18)4-5-10(9)14-11-3-1-2-6-15(11)12/h1-7H,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C13H8N2O3
Molecular Weight	240.2142
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2907188 | https://www.ncbi.nlm.nih.gov/pubmed/3814221 | Elks, J. (2014) The Dictionary of Drugs: Chemical Data, page 920, retrieved from: https://books.google.ru/books?id=0vXTBwAAQBAJ

Doqualast is an antiasthmatic and antiallergic agent. It has a mode of antiallergic action similar to that of disodium cromoglycate and inhibits antigen-induced mediator release by interfering with the calcium transport required for histamine secretion across the mast cell membrane. In rabbits, no embryotoxic or teratogenic effects of doqualast were observed. The concomitant use of doqualast and theophylline might cause drug interaction. Doqualast is thought to increase the blood free fraction of concomitantly used theophylline and to accelerate elimination of theophylline from blood.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
histamine secretion 4 Target ID: GO:0001821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2434111	Inhibitor 8297

PubMed

Title	Date	PubMed
Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on immediate allergic reactions.	1986 Nov	2434109
Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on type I allergic reactions.	1986 Nov	2434110
Immunopharmacological actions of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid. Effects on type I hypersensitivity reactions in human leukocytes and in human and monkey lungs.	1986 Nov	2434111
Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on bronchial and cutaneous allergic responses to ascaris in dogs.	1986 Nov	2434112
Effect of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid on inflammatory reactions and platelet aggregation.	1986 Nov	3493011
[Protective effect of Sm 857 (Doqualast) in allergic bronchial asthma].	1986 Nov	3543921
Immunopharmacological actions of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid. Effects on immunological reactions in mice and in humans.	1986 Nov	3814220
Study of drug interaction between the new antiallergic drug 11-oxo-11H-pyrido[2,1-b]quinazoline-2-carboxylic acid and theophylline.	1986 Nov	3814221
[Comparison of the anti-allergic and anti-asthmatic effects of SM 857 (Doqualast) and DNCG].	1987 Feb	3106950
Evaluation of different drugs in two models of immediate hypersensitivity.	1988 Mar	2899148
[Protective effect of Sm 857 on allergen-induced immediate bronchoconstriction].	1988 Nov	2907285
Teratogenicity of the antiallergic Sm 857 SE in rats versus rabbits.	1988 Oct	2907188
[Pilot study of the action of Doqualast on dietary hyperuricemia in volunteers].	1989 Sep	2574040

Patents

Sample Use Guides

In Vivo Use Guide

Single dose 50 mg/kg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 18:04:29 GMT 2023` Edited by `admin` on `Sat Dec 16 18:04:29 GMT 2023`
Record UNII	N8F510M76F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DOQUALAST

Official Name

English

doqualast [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29712